Table 1.
Laboratory test results before and after treatment.
Items | Measured value | Reference range | |
---|---|---|---|
Before treatment | After treatment | ||
RBC (×1012/L) | 3.33 | 4.07 | 3.5-5 |
Hb (g/L) | 129 | 125 | 110-150 |
MCV (fL) | 110.2 | 92.60 | 82-95 |
MCH (pg) | 38.7 | 30.70 | 27-31 |
MCHC (g/L) | 351 | 332 | 320-360 |
RBC volume distribution width (fl) | 54.0 | 39.80 | 39.0-46.0 |
Platelet (×109/L) | 388 | 231 | 100-350 |
Thrombocytocrit (%) | 0.31 | 0.23 | 0.10-0.28 |
WBC (×109/L) | 5.83 | 4.14 | 4-10 |
Vitamin B12 (pg/ml) | 74.00 | Medication | 180-914 |
Folic acid (ng/ml) | >23.90 | Medication | 3.1-19.9 |
ESR (mm/h) | 37 | 17 | 0-20 |
Homocysteine (μmol/L) | 124.1 | 11.0 | 0-20 |
GGT (U/L) | 55 | 24 | 7-45 |
A/G | 1.49 | 1.72 | 1.5-2.5 |
Intrinsic factor antibody (Au/ml) | Positive (8.92) | Negative | |
Parietal cell antibody | +1:80 | +1:80 | Negative |
ANA | +1:320 (centromere type) |
+1:160 (centromere type) |
Negative |
Anti CENP B antibody | +++ | ++ | Negative |
Anti SSA60 | + | Negative | Negative |
CCP | Negative | Negative | |
RF | Negative | Negative | Negative |
MTHFR | Mutant type (TT) | Negative | |
CYFRA21-1 (ng/ml) | 3.47 | 3.84 | 0.1-3.3 |
CA72-4 (U/ml) | 127.00 | 18.10 | 0-6.9 |
Alpha-fetoprotein (ng/ml) | 13.70 (0.01-7) | 10.08 (0.00-15) | In parentheses |
C13 breath test | Negative | Negative | Negative |
γ-globulin (%) | 14.6 | NA | 9.1-24.0 |
β2-microglobulin (%) | 6.3 | NA | 1.8-6.2 |
α1-globulin (%) | 5.2 | NA | 2.2-4.8 |
RBC, red-cell count; Hb, hemoglobin; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpusular hemoglobin concerntration; WBC, white blood cell; ESR, erythrocyte sedimentation rate; GGT, gamma-glutamyl transferase; ANA, anti-nuclear antibody; CCP, anti-cyclic citrullinated peptide antibody; RF, rheumatoid factors; MTHFR, Methylene tetrahydrofolate reductase; CA72-4, Cancer antigen CA72-4; NA, not available.
+ refers to a lighter degree, +++ refers to a heavier degree, and ++ refers to a degree between the two.